Drug reference
mobocertinib
EGFR kinase inhibitor · Antineoplastic agent
EGFR kinase inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
D
FDA category + note
Mechanism
Mobocertinib is an irreversible kinase inhibitor. Response rate to mobocertinib is lower (28%) than that of EGFR inhibitors targeting NSCLC with more common mutations (50%–80%).
Indications
advanced NSCLC with EGFR exon 20 insertional mutations progressing after chemotherapy
Side effects
Common
skin rashdiarrhea
Pregnancy & lactation
Pregnancy
D
Related guidelines
Ask House about mobocertinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team